Cardio Oncologic Complexity in Gynecological Malignancies: Integrating Nuclear Radiation Therapy, Chemotherapy, and Radical Surgery in Pacemaker Dependents Patients
Keywords:
Cardio-oncology, Gynecological malignancies, Pacemaker-dependent patients, Radiation therapy, Chemotherapy, Radical surgery, Cardiotoxicity, Multidisciplinary careAbstract
Background: The management of gynecological malignancies has become increasingly complex in patients who are pacemaker-dependent due to the potential cardiovascular risks associated with chemotherapy, radiation therapy, and radical surgical procedures. These treatment modalities, while essential for cancer control, may adversely affect cardiac function or interfere with the performance of cardiac implantable electronic devices, requiring careful multidisciplinary planning.
Objective: This review aims to summarize the current evidence on the multidisciplinary management of pacemaker-dependent patients with gynecological malignancies, with a particular focus on the integration of nuclear radiation therapy, chemotherapy, and radical surgery. It also highlights the challenges, safety considerations, and recent advances in cardio-oncology that support optimal treatment outcomes.
Methods: A comprehensive review of the published literature was performed using peer-reviewed articles, clinical practice guidelines, systematic reviews, and observational studies focusing on gynecological cancers, cardio-oncology, pacemaker management, radiation oncology, chemotherapy-induced cardiotoxicity, and perioperative care. Relevant evidence was critically analyzed to provide an updated overview of current clinical practice.
Results: Available evidence suggests that successful treatment of gynecological malignancies in pacemaker-dependent patients requires individualized risk assessment, careful radiation planning, continuous cardiac monitoring, appropriate pacemaker management, and close collaboration among gynecologic oncologists, cardiologists, radiation oncologists, medical oncologists, anesthesiologists, and electrophysiologists. Modern radiotherapy techniques, advancements in cardiac device technology, and standardized monitoring protocols have significantly reduced treatment-related complications while improving patient safety and clinical outcomes.
Conclusion: The integration of nuclear radiation therapy, chemotherapy, and radical surgery in pacemaker-dependent patients presents unique clinical challenges that demand a multidisciplinary cardio-oncology approach. Early cardiovascular evaluation, personalized treatment planning, and adherence to evidence-based guidelines are essential to minimize complications and optimize both oncological and cardiac outcomes. Further prospective studies and standardized clinical recommendations are needed to strengthen evidence-based management strategies for this high-risk patient population
Downloads
References
1. Suneja G, Viswanathan A. Gynecologic Malignancies. Hematol Oncol Clin North Am. 2020;34(1):71-89. doi:10.1016/j.hoc.2019.08.018
2. Blair AR, Casas CM. Gynecologic cancers. Prim Care. 2009 Mar;36(1):115-130, ix. doi:10.1016/j.pop.2008.10.001. PMID: 19231605.
3. Bray f, laversanne m, sung h, et al. global cancer statistics 2022: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. ca cancer j clin. 2024;74(3):229-263. doi:10.3322/caac.21834
4. Salehi AM, Shahbazi F, Garavand R, Kamkari S, Jenabi E. BMC Women's Health. 2025;25:596. doi:10.1186/s12905-025-03961-3. PMID: 40999424.
5. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2024 (CA: A Cancer Journal for Clinicians).
6. Lyon AR, Lopez-Fernandez T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology. Eur Heart J. 2022;43(41):4229-4361.
7. Parashar S, Akhter N, Paplomata E, et al. Cancer Treatment-Related Cardiovascular Toxicity in Gynecologic Malignancies: JACC: Cardio Oncology State-of-the-Art Review. JACC CardioOncol. 2023;5(2):159-173.
8. Curigliano G, Lenihan D, Fradley M, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO Consensus Recommendations. Ann Oncol. 2020;31(2):171-190.
9. Hurkmans CW, Knegjens JL, Oei BS, et al. Radiat Oncol. 2012;7:198. doi:10.1186/1748-717X-7-198.
10. Qiao H, Jiang F, Ning P, et al. Acta Cardiol Sin. 2023;39(6):807-816. doi:10.6515/AC .202311_39(6).20230828A
11. Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al.2016 ESC Position Paper on cancer treatments and cardiovascular toxicity and prevention. Eur Heart J. 2016;37(36):2768–2801
12. Plana JC, Galderisi M, Barac A, et al.Expert consensus for multimodality imaging evaluation during cancer therapy. J Am Soc Echocardiogr. 2014;27(9):911–939.
13. WHO. Cervical cancer: key facts and global guidelines update. World Health Organization (WHO). 2023
14. Colombo N, Sessa C, du Bois A, et al.ESMO-ESGO consensus conference recommendations on ovarian cancer. Ann Oncol. 2019;30(5):672–705.
15. Concin N, Creutzberg CL, Vergote I, et al.ESMO-ESGO-ESTRO consensus guidelines for endometrial cancer. Int J Gynecol Cancer. 2021;31(1):12–39.
16. ESGO guidelines for the management of vulvar cancer. Int J Gynecol Cancer. 2020;30(5):652–670
17. NCCN Clinical Practice Guidelines in Oncology.Cervical Cancer / Ovarian Cancer / Endometrial Cancer / Uterine Neoplasms (latest versions). National Comprehensive Cancer Network (NCCN). 2025.
18. Zaremba T, Jakobsen AR, Søgaard M, Thøgersen AM, Johansen MB, Madsen LB. Radiotherapy in patients with pacemakers and implantable cardioverter-defibrillators: A literature review. Europace. 2016;18(4):479-491. doi:10.1093/europace/euv300.
19. Virani SA, Dent S, Brezden-Masley C, et al.Canadian Cardiovascular Society guidelines for evaluation and management of cardiovascular complications of cancer therapy.Can J Cardiol. 2016;32(7):831–841.
20. Lyon AR, López-Fernández T, Couch LS, et al.2022 ESC Guidelines on cardio-oncology developed in collaboration with EHA, ESTRO and IC-OS. Eur Heart J. 2022;43(41):4229–4361.
21. Kusumoto FM, Schoenfeld MH, Barrett C, et al. 2018 ACC/AHA/HRS guideline on bradycardia and conduction delay.Circulation. 2019;140(8):e382–e482.
22. Glikson M, Nielsen JC, Kronborg MB, et al.2013 ESC pacing and CRT guidelines. Eur Heart J. 2013;34(29):2281–2329.
23. Querleu D, et al. Radical hysterectomy and pelvic surgery classification. Int J Gynecol Cancer. 2017.
24. Zaremba T, Jakobsen AR, Søgaard M, et alRadiation effects on pacemakers/ICDs. Europace. 2016;18:479–491.https://doi.org/10.1093/europace/euv135
25. Grant JD, Kudchadker RJ, Palta M, et al.Radiotherapy in patients with cardiac devices. Int J Radiat Oncol Biol Phys. 2015;91(5):973–980.https://doi.org/10.1016/j.ijrobp.2015.01.00
26. Yeh ETH, Bickford CL. Cardiovascular complications of cancer therapy: Incidence, pathogenesis, detection, and management. J Am Coll Cardiol. 2009;53(24):2231-2247. doi:10.1016/j.jacc.2009.02.050
27. Mutch DG, et al. Surgical management of advanced gynecologic malignancies. Obstet Gynecol. 2019.
28. Indik JH, Gimbel JR, Abe H, et al. 2023 HRS Expert Consensus Statement on magnetic resonance imaging and radiation exposure in patients with cardiovascular implantable electronic devices. Heart Rhythm. 2023
29. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004;56(2):185-229. doi:10.1124/pr.56.2.6.
30. Totzeck M, Mincu RI, Rassaf T. Cardiovascular adverse events in patients with cancer treated with bevacizumab: A meta-analysis. J Am Heart Assoc. 2017;6:e006278.
31. Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368(11):987-998. doi:10.1056/NEJMoa1209825.
32. Benedict SH, Yenice KM, Followill D, et al. Stereotactic body radiation therapy: The report of AAPM Task Group 101. Med Phys. 2010;37(8):4078-4101. doi:10.1118/1.3438081.
33. Viswanathan AN, Beriwal S, De Los Santos JF, et al. American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Brachytherapy. 2012;11(1):33-46. doi:10.1016/j.brachy.2011.07.002.
34. Zaremba T, Jakobsen AR, Søgaard M, Thøgersen AM, Johansen MB, Madsen LB. Radiotherapy in patients with pacemakers and implantable cardioverter-defibrillators: A literature review. Europace. 2016;18(4):479-491. doi:10.1093/europace/euv300.
35. European Society of Cardiology. 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery. Eur Heart J. 2022.
36. Crossley GH, Poole JE, Rozner MA, et al. The Heart Rhythm Society (HRS)/American Society of Anesthesiologists Expert Consensus Statement on the perioperative management of patients with cardiac implantable electronic devices. Heart Rhythm. 2011;8(7):1114-1154
37. Herrmann J. Vascular toxic effects of cancer therapies. Nat Rev Cardiol. 2020;17(8):503–522. doi:10.1038/s41569-020-0348-1.
38. European Society of Cardiology. 2022 ESC Guidelines on cardio-oncology. Eur Heart J. 2022;43(41):4229–4361
39. Yeh ETH, Bickford CL. Cardiovascular complications of cancer therapy: Incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 2009;53(24):2231–2247.
40. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials. Cancer. 2003;97(11):2869–2879.
41. Totzeck M, Mincu RI, Rassaf T. Cardiovascular adverse events in patients with cancer treated with bevacizumab: A meta-analysis of more than 20,000 patients. J Am Heart Assoc. 2017;6:e006278.
42. Plana JC, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy. J Am Soc Echocardiogr. 2014.
43. Herrmann J. Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. Nat Rev Cardiol. 2020.
44. Cardiotoxicity of anticancer drugs: molecular mechanisms and strategies for cardioprotection. Front Cardiovasc Med. 2022.
45. Cardiotoxicity of anti-cancer drugs: cellular mechanisms and clinical implications. Front Cardiovasc Med. 2023.
46. Cancer therapy-induced cardiotoxicity: mechanisms and clinical implications. 2025.
47. Chemotherapy-induced cardiotoxicity: mechanisms, detection and management. 2025.
48. Mechanisms of cardiotoxicity of cancer chemotherapeutic agents. 2016.
49. Cardiotoxicity of chemotherapy and targeted agents. 2021.
50. Chemotherapy-induced cardiotoxicity: overview of the molecular and biochemical mechanisms. 2015.
51. Chemotherapy-induced cardiotoxicity. 2013.
52. Pathophysiological mechanisms of cardiotoxicity in chemotherapy. 2020.
53. Cardiotoxicity induced by traditional chemotherapy: mechanisms and mitigation strategies. 2026.
54. Shah NR, et al. Cardio-oncology in clinical practice: contemporary approaches to surveillance and management. Eur Heart J. 2021.
55. Armenian SH, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: ASCO guideline. J Clin Oncol. 2017.
56. Cardinale D, et al. Anthracycline-induced cardiomyopathy: clinical relevance and monitoring. J Am Coll Cardiol. 2010.
57. Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol. 2005.
58. Feldman AM, Valentijn AJ. Cardiotoxicity of cancer therapeutics: mechanisms and clinical consequences. Circulation. 2016.
59. de Azambuja E, et al. Trastuzumab-related cardiac dysfunction: risk factors and management. J Clin Oncol. 2010.
60. Suter TM, et al. Trastuzumab-associated cardiac adverse effects in clinical trials. J Clin Oncol. 2007.
61. Moik F, et al. Cancer therapy-related arrhythmias. JACC CardioOncol. 2021.
62. Lenihan DJ, et al. Cardiotoxicity monitoring in oncology: biomarkers and imaging. J Am Coll Cardiol. 2018.
63. Cardinale D, et al. Role of troponin in predicting chemotherapy-induced cardiotoxicity. Circulation. 2000.
64. Abdel-Qadir H, et al. Biomarkers for early detection of cardiotoxicity in cancer therapy. Eur Heart J. 2022.
65. Thavendiranathan P, et al. Echocardiography in cardiac surveillance during cancer therapy. J Am Coll Cardiol. 2017.
66. Plana JC, et al. Imaging cardiac function during and after cancer therapy. Eur Heart J Cardiovasc Imaging. 2018.
67. Yeh ETH, Bickford CL. Cardiovascular complications of cancer therapy: incidence, mechanisms, and management. Circulation. 2009.
68. Bansal N, et al. Cancer therapy-related cardiac dysfunction. Heart. 2020.
69. Vejpongsa P, Yeh ETH. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. J Am Coll Cardiol. 2014.
70. Curigliano G, et al. Management of cardiac disease in cancer patients throughout oncological treatment. ESMO consensus. 2020.
71. Lyon AR, et al. Baseline cardiovascular assessment before cancer therapy. Eur J Heart Fail. 2020.
72. Armenian SH, et al. Cardiovascular screening and surveillance in cancer patients. J Clin Oncol. 2022.
73. Dobson R, et al. Monitoring for cardiotoxicity in patients receiving cancer therapy. BMJ. 2019.
74. Eliott AD, et al. Pacemaker and ICD management during surgery. Anaesthesia. 2018.
75. Crossley GH, et al. 2011 HRS/ASA expert consensus statement on perioperative management of patients with pacemakers and ICDs. Heart Rhythm. 2011.
76. HRS/ASA perioperative CIED management updates. Heart Rhythm. 2020.
77. Leung LW, et al. Electrocautery and implanted cardiac devices: perioperative precautions. Anesth Analg. 2019.
78. Madigan JD, et al. Management of cardiac implantable electronic devices during procedures. Pacing Clin Electrophysiol. 2017.
79. Zecchin M, et al. Surgery in pacemaker-dependent patients: practical management strategies. Europace. 2021.
80. Stone ME, et al. Intraoperative management of the patient with a pacemaker. Surg Clin North Am. 2020.
81. Misiri J, et al. Electromagnetic interference and implanted cardiac devices. Mayo Clin Proc. 2012.
82. Kanal E, et al. MRI safety in patients with pacemakers and ICDs. Radiology. 2017.
83. Nazarian S, et al. MRI in patients with non-MRI-conditional devices. N Engl J Med. 2017.
84. Russo RJ, et al. Assessing the risks of MRI in patients with cardiac devices. Circulation. 2017.
85. HRS expert consensus on MRI and CIEDs. Heart Rhythm. 2017.
86. Varma N, et al. Remote monitoring of cardiac devices: clinical utility. J Am Coll Cardiol. 2018.
87. Singh JP, et al. Radiation exposure and pacemaker malfunction. Heart Rhythm. 2012.
88. Hurkmans CW, et al. Recommendations for radiotherapy in patients with pacemakers. Radiother Oncol. 2012.
89. Gossman MS, et al. Device management during radiotherapy. Pract Radiat Oncol. 2017.
90. Miften M, et al. AAPM TG-203: management of radiotherapy patients with implanted cardiac devices. Med Phys. 2019.
91. Marbach JR, et al. The tolerance of pacemakers to ionizing radiation. Int J Radiat Oncol Biol Phys. 1994.
92. Zaremba T, et al. Cardiac implantable devices and modern radiotherapy techniques. Clin Oncol. 2020.
93. Grant JD, et al. Interference between radiotherapy and pacemakers. J Clin Oncol. 2015.
94. Brambs CE, et al. Pacemakers in oncology patients: radiation safety and monitoring. Strahlenther Onkol. 2021.
95. Shah AD, et al. Device malfunction during cancer therapy. JACC Clin Electrophysiol. 2022.
96. Perioperative management of implanted cardiac devices in major surgery. Br J Anaesth. 2019.
97. Mazur A, et al. Electrosurgery and cardiac implantable devices. Clin Cardiol. 2018.
98. Ellenbogen KA, et al. Clinical cardiac pacing, defibrillation, and resynchronization therapy. 2019.
99. Connor JP, et al. Radical hysterectomy in early cervical cancer: surgical standards and perioperative assessment. Gynecol Oncol. 2018.
100. Berek JS, et al. Ovarian cancer cytoreductive surgery: principles and outcomes. Int J Gynecol Cancer. 2020.
101. Höckel M, et al. Pelvic exenteration for recurrent gynecologic malignancies. Lancet Oncol. 2016.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
